Non-cystic fibrosis bronchiectasis
Drug research and approvals for non-cystic fibrosis bronchiectasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 24 studies of non-cystic fibrosis bronchiectasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 8 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 24
- Trials authorized in Canada: 8
- FDA orphan approvals: 0
- EU medicines: 1
- Phase 1 Study to Assess the Effects of HSK31858 on the QT/QTc Interval in Healthy Chinese ParticipantsNCT07915024 · Phase 1 · Haisco Pharmaceutical Group Co., Ltd. · starts Aug 6, 2026
- Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Renal ImpairmentNCT07915011 · Phase 1 · Haisco Pharmaceutical Group Co., Ltd. · starts May 26, 2026
- Investigation of Pharmacokinetics, Safety of HSK31858 in Subjects With Hepatic ImpairmentNCT07913009 · Phase 1 · Haisco Pharmaceutical Group Co., Ltd. · starts Mar 16, 2026
- Diagnostic Value of Oropharyngeal Suction and Effect of Respiratory Physiotherapy on the Detection of Microorganisms in…NCT07903792 · Not applicable · Corporacion Parc Tauli · starts Jun 1, 2026
- High-Intensity Interval Exercise in Bronchiectasis PatientsNCT07805174 · Not applicable · Saglik Bilimleri Universitesi · starts Mar 27, 2026
- A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With…NCT07720375 · Phase 2 · UCB Biopharma SRL · starts Aug 5, 2026
- A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisNCT07616375 · Phase 3 · Haisco Pharmaceutical Group Co., Ltd. · starts Sep 28, 2025
- Azithromycin to Modify Bronchiectasis Exacerbation RiskNCT07608328 · Phase 4 · Assiut University · starts Jun 29, 2026
- Bronchiectasis Phenotype Identification ModelNCT07599969 · Not reported · Assiut University · starts Sep 11, 2025
| Nov 10, 2026 | A phase 2b, multicenter, randomized, double-blind, parallel-group, placebo-controlled, dose range finding study to evaluate the efficacy, safety, and…CSL787 | CSL | Pending |
| Mar 20, 2026 | A randomized, double-blinded, placebo-controlled, parallel-group, phase 2a participants with non-cystic fibrosis bronchiectasis (NCFB) study to assess the…SAR445399 | Sanofi-Aventis Canada Inc | Ongoing |
| Feb 28, 2024 | A randomized, double-blind, placebo-controlled, parallel group, proof-ofconcept (POC) study to assess the efficacy, safety and tolerability of itepekimab, in…Itepekimab (SAR440340; REGN3500) | Sanofi-Aventis Canada Inc | Closed |
| Feb 4, 2021 | A multicentre, randomised, double-blind, parallel-group, placebo-controlled, 52 week, phase III study with an open-label extension to evaluate the efficacy and…Benralizumab (MEDI-563) | AstraZeneca Pharmaceuticals | Ongoing |
| Dec 3, 2020 | A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of brensocatib administered once daily for 52…Brensocatib (INS1007) | Insmed | Closed |
| Jan 31, 2018 | A double-blind, placebo controlled, multi-center, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled promixin®…Colistimethate | Zambon | Closed |
| Apr 17, 2014 | A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pulmaquin® in the management of chronic lung…Pulmaquin | Aradigm | Closed |
| Mar 7, 2014 | A multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pulmaquin® in the management of chronic lung…Pulmaquin | Aradigm | Closed |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Nov 18, 2025 | BrinsupriBrensocatib | Insmed Netherlands B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA